#	Pagina
attuale pagina	/open-h2020/projects/196474/index.html

Opendata, web and dolomites

STROBE

Sustained Release Ocular Bevacizumab for the treatment of wet acute macular degeneration

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

STROBE project word cloud

Explore the words cloud of the STROBE project. It provides you a very rough idea of what is the project "STROBE" about.

age pharmaceuticals degeneration vision almost drug sr safety economic life ocular polymers feasibility wet acute suitable encapsulate aged sustained manufactured central patient amd treatment critical release viability effectiveness biodegradable distortion criticalmix verify prototype macular always acceptability blurring quality manufacturing bevacizumab blindness eye causes

Project "STROBE" data sheet

The following table provides information about the project.

Coordinator	CRITICAL PHARMACEUTICALS LIMITED Organization address address: BIOCITY NOTTINGHAM - PENNYFOOT STREET city: NOTTINGHAM postcode: NG1 1GF website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	United Kingdom [UK]
Project website	http://www.criticalpharmaceuticals.com
Total cost	71˙429 €
EC max contribution	50˙000 € (70%)
Programme	1. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument) 2. H2020-EU.2.1.2. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies)
Code Call	H2020-SMEINST-1-2014
Funding Scheme	SME-1
Starting year	2015
Duration (year-month-day)	from 2015-05-01 to 2015-10-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	CRITICAL PHARMACEUTICALS LIMITED CRITICAL PHARMACEUTICALS LIMITED Organization address address: BIOCITY NOTTINGHAM - PENNYFOOT STREET city: NOTTINGHAM postcode: NG1 1GF website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (NOTTINGHAM)	coordinator	50˙000.00

Map

Project objective

Sustained Release Ocular Bevacizumab for the treatment of wet acute macular degeneration

This feasibility study is to verify the technical and economic viability of a sustained release bevacizumab product (SR Bevacizumab) to improve the safety, cost-effectiveness and patient acceptability for the treatment of wet age-related macular degeneration (AMD). AMD is the leading cause of blindness in those aged over 50 and causes blurring, distortion and loss of central vision and almost always affects quality of life. Prototype SR Bevacizumab products will be manufactured using CriticalMix, an advanced manufacturing and processing technology developed by Critical Pharmaceuticals, which will encapsulate bevacizumab in biodegradable polymers suitable for sustained release of the drug in the eye.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "STROBE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "STROBE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.3.1.;H2020-EU.2.1.2.)

S3D (2015)

Feasibility study to determine the use of ITS technology to replace nuclear density meters in mining, dredging and other areas of hydraulic transport.